"Drug Substitution" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The practice of replacing one prescribed drug with another that is expected to have the same clinical or psychological effect.
- Drug Substitution
- Drug Substitutions
- Substitution, Drug
- Substitutions, Drug
- Therapeutic Substitution
- Substitution, Therapeutic
- Substitutions, Therapeutic
- Therapeutic Substitutions
- Drug Switching
- Drug Switchings
- Switching, Drug
- Switchings, Drug
- Generic Substitution
- Generic Substitutions
- Substitution, Generic
- Substitutions, Generic
Below are MeSH descriptors whose meaning is more general than "Drug Substitution".
Below are MeSH descriptors whose meaning is more specific than "Drug Substitution".
This graph shows the total number of publications written about "Drug Substitution" by people in this website by year, and whether "Drug Substitution" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Drug Substitution" by people in Profiles.
Ambulatory Transition from Parenteral Prostanoid to Inhaled Treprostinil in Patients with Pulmonary Arterial Hypertension. Lung. 2020 02; 198(1):53-58.
Outcome of elective switching to vedolizumab in inflammatory bowel disease patients under tumor necrosis factor antagonist-maintained clinical remission. J Gastroenterol Hepatol. 2019 Dec; 34(12):2090-2095.
Psoriasis Area and Severity Index response in moderate-severe psoriatic patients switched to adalimumab: results from the OPPSA study. J Eur Acad Dermatol Venereol. 2018 Oct; 32(10):1737-1744.
Impact of previous biologic use on the efficacy and safety of brodalumab and ustekinumab in patients with moderate-to-severe plaque psoriasis: integrated analysis of the randomized controlled trials AMAGINE-2 and AMAGINE-3. Br J Dermatol. 2018 08; 179(2):320-328.
Exceptional response to olaparib in BRCA2-altered urothelial carcinoma after PD-L1 inhibitor and chemotherapy failure. Eur J Cancer. 2018 06; 96:128-130.
Generic Substitution Rates of Oral Contraceptives and Associated Out-of-Pocket Cost Savings Between January 2010 and December 2014. JAMA Intern Med. 2018 04 01; 178(4):561-563.
Current Trends in Anticoagulation Bridging for Patients With Chronic Atrial Fibrillation on Warfarin Undergoing Endoscopy. Am J Cardiol. 2018 06 15; 121(12):1548-1551.
Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. J Am Acad Dermatol. 2017 Mar; 76(3):418-431.
The efficacy and safety of continued hydroxycarbamide therapy versus switching to ruxolitinib in patients with polycythaemia vera: a randomized, double-blind, double-dummy, symptom study (RELIEF). Br J Haematol. 2017 Jan; 176(1):76-85.
New Onset Hypertension Linked to Generic Cyclosporine Substitution in Post-Renal Transplant Patient. Am J Nephrol. 2016; 44(3):219-23.